Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-07-01, Stock:PFE, The news for the past five days is as follows:
2019-06-24: NEWS1: Why These Innovative Biotech ETFs Soaring.NEWS2: Why These Innovative Biotech ETFs Soaring.NEWS3: Comparing PFE’s and BMY’s Revenue Trajectory.NEWS4: Why These Innovative Biotech ETFs Soaring.NEWS5: This Biotech Stock Is Facing A 'Whale' As Pfizer Unveils Gene Therapy Data.NEWS6: What Analysts Recommend for Pfizer and Bristol-Myers Squibb.NEWS7: BioMarin Gets $15M From Pfizer on Talzenna's European Nod.NEWS8: BioMarin Gets $15M From Pfizer on Talzenna's European Nod.NEWS9: U.S. Senate Takes on Big Tech, Plus &quot;Merger Monday&quot;.NEWS10: Eldorado to Buy Caesars.NEWS11: Pfizer's Talzenna Gets Approval in Europe for Breast Cancer.NEWS12: Pfizer's Talzenna Gets Approval in Europe for Breast Cancer.NEWS13: Read This Before You Buy Any New Cancer Drug Stocks.NEWS14: Read This Before You Buy Any New Cancer Drug Stocks.NEWS15: BioMarin Gets $15M From Pfizer on Talzenna's European Nod.NEWS16: U.S. Senate Takes on Big Tech, Plus &quot;Merger Monday&quot;.NEWS17: Pfizer's Talzenna Gets Approval in Europe for Breast Cancer.
2019-06-25: NEWS1: Stocks Swing Lower As Rate Cut Optimism Dampens.NEWS2: Stocks Swing Lower As Rate Cut Optimism Dampens.NEWS3: Pfizer (PFE) Flat As Market Sinks: What You Should Know.NEWS4: 3 Healthcare Stocks to Buy With the Market Near All-Time Highs.NEWS5: 3 Healthcare Stocks to Buy With the Market Near All-Time Highs.NEWS6: After Hours Most Active for Jun 25, 2019 :  DIS, TI, LC, PFE, NEM, QD.NEWS7: After Hours Most Active for Jun 25, 2019 :  DIS, TI, LC, PFE, NEM, QD.NEWS8: Abbvie Decides to Acquire Allergan.NEWS9: Noteworthy ETF Inflows: SPY, BRK.B, DIS, PFE.NEWS10: Noteworthy ETF Inflows: SPY, BRK.B, DIS, PFE.NEWS11: AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20.NEWS12: Dow Movers: GS, JNJ.NEWS13: Dow Movers: GS, JNJ.NEWS14: Think AbbVie Is Overpaying for Allergan? Pfizer Offered Way More in 2015.NEWS15: Abbvie Decides to Acquire Allergan.NEWS16: Pfizer’s Oncology Treatment Growth Drivers.NEWS17: AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20.NEWS18: Comparing PFE’s and BMY’s Expense Trends.NEWS19: How PFE’s and BMY’s EPS Trends Compare.NEWS20: Allergan stock surges on news that Abbvie will buy Botox maker in a $63 billion deal.
2019-06-26: NEWS1: 3 Dividend Stocks That Could Pay You the Rest of Your Life.NEWS2: Conatus' Emricasan Lags Primary Goal in Liver Function Study.NEWS3: Conatus' Emricasan Lags Primary Goal in Liver Function Study.NEWS4: Comparing PFE’s and BMY’s Immunology Drugs.NEWS5: Conatus' Emricasan Lags Primary Goal in Liver Function Study.NEWS6: 3 Dividend Stocks That Could Pay You the Rest of Your Life.NEWS7: 3 Dividend Stocks That Could Pay You the Rest of Your Life.NEWS8: Pfizer (PFE) Flat As Market Sinks: What You Should Know.NEWS9: Pfizer (PFE) Flat As Market Sinks: What You Should Know.NEWS10: 3 Biopharma Stocks to Buy for Income.NEWS11: 3 Biopharma Stocks to Buy for Income.
2019-06-27: NEWS1: Pfizer names former FDA chief Scott Gottlieb to its board.NEWS2: Scott Gottlieb Elected to Pfizer’s Board of Directors.NEWS3: Pfizer Declares Third-Quarter 2019 Dividend.NEWS4: Lilly's Study on Higher Doses of Trulicity Meets Endpoint.NEWS5: Lilly's Study on Higher Doses of Trulicity Meets Endpoint.NEWS6: Draper laboratory signs 'organ-on-chip' development deal with Bristol-Myers Squibb.NEWS7: Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits.NEWS8: Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits.NEWS9: Lilly's Study on Higher Doses of Trulicity Meets Endpoint.NEWS10: Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits.NEWS11: Ex-FDA boss joins Pfizer 83 days after leaving US drug regulator.
2019-06-28: NEWS1: AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study.NEWS2: AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study.NEWS3: Here's Why Sarepta Therapeutics Is Surging Today.NEWS4: Here's Why Sarepta Therapeutics Is Surging Today.NEWS5: These Are The 5 Worst Dow Jones Stocks In The First Half Of 2019.NEWS6: AstraZeneca's Imfinzi Meets Endpoint in Lung Cancer Study.NEWS7: Daily Dividend Report: FNLC, PFE, T, NYT, BFS.NEWS8: Daily Dividend Report: FNLC, PFE, T, NYT, BFS.NEWS9: After Hours Most Active for Jun 27, 2019 :  CZR, UBER, PFE, SYF, AAPL, TRUE, MU, VEON, BAC, NKE, KO, QCOM.NEWS10: After Hours Most Active for Jun 27, 2019 :  CZR, UBER, PFE, SYF, AAPL, TRUE, MU, VEON, BAC, NKE, KO, QCOM.NEWS11: Gene Therapy Battle: Pfizer's Test Results Sent This Biotech Stock Flying.NEWS12: Here&apos;s Why Sarepta Therapeutics Is Surging Today.NEWS13: Pfizer Announces Results from Phase 3 Trial of Revatio® (Sildenafil Citrate) in Newborns with Persistent Pulmonary Hypertension.NEWS14: Sarepta Therapeutics Soars as Pfizer's Competing Drug Shows Safety Problems.NEWS15: Street Crowns Sarepta DMD Gene Therapy King After Pfizer Results.NEWS16: Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger.NEWS17: Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger.NEWS18: Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop.NEWS19: Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop.NEWS20: Sarepta surges after Pfizer gene therapy data raises safety concerns.NEWS21: Pfizer gene therapy for rare muscle disease shows promise in small, early study.NEWS22: Pfizer Presents Initial Clinical Data on Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (DMD).NEWS23: Pharma Stock Roundup: ABBV to Buy AGN, BMY to Sell CELG's Otezla to Close Merger.NEWS24: Can Roche's #1 Therapeutic Area With $28 Billion In Revenue Grow Further?.NEWS25: Can Roche's #1 Therapeutic Area With $28 Billion In Revenue Grow Further?.NEWS26: Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop.NEWS27: Pfizer's Avastin biosimilar wins FDA approval.NEWS28: Pfizer says FDA has approved its oncology biosimilar Zirabev to treat 5 types of cancer.NEWS29: Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr).NEWS30: The Daily Biotech Pulse: Chiasma To Join R3K Index, EU Rejects Amgen's Osteoporosis Drug Application, Karuna IPO.

Answer: Rise